Who We Are

HMR starts trial of potential treatment for major symptoms of Alzheimer’s disease

Heptares announced in a press release today that the first subject has been dosed in this ‘phase 1 clinical study of novel selective muscarinic M4 agonist in development to treat major symptoms of Alzheimer’s disease.’ ‘The compound stimulates M4 receptor activity in the brain with high selectivity, and offers the possibility for an improved safety profile over previous muscarinic receptor agonists, which have been associated with adverse effects elsewhere in the body leading to safety and tolerability issues.’

Back to list
National Training AwardsCyber EssentialsDigital XRaidA proud member of UK BioIndustry Associationone nucleus